Research location
Canal Fulton
Ohio, United States
Advertisement
Research activity in Canal Fulton
Ohio, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 32 trials and 32 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Canal Fulton
32 linked trials · page 1 of 1A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137 · 2015-06-16 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 DiabetesNCT02128932 · 2014-08-04 · 1 site observation
COMPLETED
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusNCT01989754 · 2014-01-16 · 1 site observation
COMPLETED
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic PatientsNCT01798706 · 2013-06-01 · 1 site observation
COMPLETED
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsNCT01730534 · 2013-04-25 · 1 site observation
COMPLETED
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 HypertensionNCT01508026 · 2012-01-01 · 1 site observation
COMPLETED
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesNCT01272219 · 2011-06-01 · 1 site observation
COMPLETED
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminNCT01376557 · 2011-06-01 · 1 site observation
COMPLETED
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive MedicationNCT01195662 · 2010-10-01 · 1 site observation
COMPLETED
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerNCT01137474 · 2010-07-01 · 1 site observation
COMPLETED
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusNCT01144338 · 2010-06-18 · 1 site observation
COMPLETED
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentNCT01064414 · 2010-06-01 · 1 site observation
COMPLETED
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.NCT01128894 · 2010-05-01 · 1 site observation
COMPLETED
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsNCT01107886 · 2010-05-01 · 1 site observation
COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideNCT00968812 · 2009-09-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineNCT00976391 · 2009-09-01 · 1 site observation
COMPLETED
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 DiabetesNCT00859898 · 2009-04-01 · 1 site observation
COMPLETED
Efficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesNCT00838903 · 2009-02-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesNCT00838916 · 2009-02-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 DiabetesNCT00839527 · 2009-02-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Albiglutide in Type 2 DiabetesNCT00849017 · 2009-01-01 · 1 site observation
COMPLETED
Safety and Efficacy of Albiglutide in Type 2 DiabetesNCT00849056 · 2009-01-01 · 1 site observation
COMPLETED
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release TabletsNCT00643851 · 2008-06-01 · 1 site observation
COMPLETED
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-NaiveNCT00495469 · 2007-08-17 · 1 site observation
COMPLETED
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)NCT00500331 · 2007-01-23 · 1 site observation
COMPLETED
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 DiabetesNCT00411892 · 2006-11-29 · 1 site observation
TERMINATED
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. MetforminNCT00386100 · 2006-10-01 · 1 site observation
COMPLETED
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With SulfonylureasNCT00313313 · 2006-04-01 · 1 site observation
COMPLETED
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy AloneNCT00295633 · 2006-03-01 · 1 site observation
COMPLETED
Study of Muraglitazar Versus Pioglitazone in Type 2 DiabetesNCT00106808 · 2005-08-01 · 1 site observation
COMPLETED
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard TherapyNCT00095134 · 2004-10-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.